Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest

Fig. 2

Characterization of the combined VTX-1-AdnaDetect workflow with cell lines. ❶ The indicated number of 22Rv1 cells was analyzed with AdnaDetect. ❷ Different quantities of 22Rv1 cells (12, 60, 68, 6, 9, 0) were mixed with a defined number of WBCs (0, 1000, 3000, 1000, 3000, 1000 cells, respectively) and analyzed with AdnaDetect. ❸ Fifty 22Rv1 cells were spiked into 4 mL blood from healthy donors, plasma depleted, and run for 3 cycles with the VTX-1, then the output from each cycle analyzed for AR-V7 and AR expression with AdnaDetect. AR: androgen receptor; AR-V7: AR splice variant 7; WBC: white blood cell; HD: healthy donor

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us